Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alzheimer's Psychosis Studies Should Measure Improved Functional Status

Executive Summary

Studies of drugs for psychosis related to Alzheimer's disease should measure improvement in patients' functional status as well as amelioration of symptoms of psychosis, FDA's Psychopharmacologic Drugs Advisory Committee agreed at its March 9 meeting.

You may also be interested in...



J&J Product Targeting Histamine H3 Receptor Moves Into Clinic

Johnson & Johnson is moving a drug candidate targeting the histamine H3 receptor into clinical development in half the time it has historically taken to advance a candidate, J&J Pharmaceuticals Group Worldwide Chairman William Weldon told an April 18 teleconference.

J&J Product Targeting Histamine H3 Receptor Moves Into Clinic

Johnson & Johnson is moving a drug candidate targeting the histamine H3 receptor into clinical development in half the time it has historically taken to advance a candidate, J&J Pharmaceuticals Group Worldwide Chairman William Weldon told an April 18 teleconference.

Agitation Should Be Called Nonspecific Symptom Across Diseases - Lilly

Agitation should be defined as a nonspecific symptom across a range of disease states, Lilly Zyprexa Product Team Leader Alan Breier, MD, proposed at a March 9 meeting of the FDA Psychopharmacologic Drugs Advisory Committee.

Related Content

UsernamePublicRestriction

Register

ID1128360

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel